HOXA-AS2 promotes type I endometrial carcinoma via miRNA-302c-3p-mediated regulation of ZFX.
Endometrial carcinoma
HOXA-AS2
MiRNA-302c-3p
YKL-40
ZFX
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
02
2020
accepted:
21
07
2020
entrez:
8
8
2020
pubmed:
8
8
2020
medline:
8
8
2020
Statut:
epublish
Résumé
HOXA cluster antisense RNA2 (HOXA-AS2), a long-chain non-coding RNA, plays an important role in the behavior of various malignant tumors. The roles of HOXA-AS2 in endometrial cancer remain unclear. We test expression levels of HOXA-AS2, miRNA-302c-3p, the transcription factor zinc finger X-chromosomal protein (ZFX), and the chitinase-like protein YKL-40 in endometrial carcinoma by qRT-PCR and western blotting. Luciferase reporter and qRT-PCR assays were conducted to identify potential binding sites of HOXA-AS2 to miRNA-302c-3p. Cell cycle, migration and invasion ability of endometrial cancer cells were investigated using flow-cytometric analysis, CCK-8 and transwell assays, respectively. HOXA-AS2 levels were significantly increased in endometrial cancer specimens compared to normal endometrial specimens. Upregulated HOXA-AS2 promoted invasion and proliferation of type I endometrial cancer cells. HOXA-AS2 silenced miRNA-302c-3p by binding to it. MiRNA-302c-3p negatively regulates ZFX and YKL-40. Thus HOXA-AS2 promotes the development of type I endometrial cancer via miRNA-302c-3p-mediated regulation of ZFX. These findings suggest that HOXA-AS2 can act as a new therapeutic target for type I endometrial cancer.
Sections du résumé
BACKGROUND
BACKGROUND
HOXA cluster antisense RNA2 (HOXA-AS2), a long-chain non-coding RNA, plays an important role in the behavior of various malignant tumors. The roles of HOXA-AS2 in endometrial cancer remain unclear.
METHODS
METHODS
We test expression levels of HOXA-AS2, miRNA-302c-3p, the transcription factor zinc finger X-chromosomal protein (ZFX), and the chitinase-like protein YKL-40 in endometrial carcinoma by qRT-PCR and western blotting. Luciferase reporter and qRT-PCR assays were conducted to identify potential binding sites of HOXA-AS2 to miRNA-302c-3p. Cell cycle, migration and invasion ability of endometrial cancer cells were investigated using flow-cytometric analysis, CCK-8 and transwell assays, respectively.
RESULTS
RESULTS
HOXA-AS2 levels were significantly increased in endometrial cancer specimens compared to normal endometrial specimens. Upregulated HOXA-AS2 promoted invasion and proliferation of type I endometrial cancer cells. HOXA-AS2 silenced miRNA-302c-3p by binding to it. MiRNA-302c-3p negatively regulates ZFX and YKL-40. Thus HOXA-AS2 promotes the development of type I endometrial cancer via miRNA-302c-3p-mediated regulation of ZFX.
CONCLUSIONS
CONCLUSIONS
These findings suggest that HOXA-AS2 can act as a new therapeutic target for type I endometrial cancer.
Identifiants
pubmed: 32760226
doi: 10.1186/s12935-020-01443-0
pii: 1443
pmc: PMC7393821
doi:
Types de publication
Journal Article
Langues
eng
Pagination
359Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Cell Biochem. 2013 Oct;114(10):2375-83
pubmed: 23649634
J Biosci. 2017 Mar;42(1):103-111
pubmed: 28229969
Med Oncol. 2013 Mar;30(1):484
pubmed: 23392577
Int J Biochem Cell Biol. 2014 Jun;51:45-52
pubmed: 24691276
Int J Oncol. 2015 Aug;47(2):465-72
pubmed: 26094604
Cancer Biol Ther. 2015;16(10):1462-70
pubmed: 26230915
Breast Cancer Res Treat. 2011 Nov;130(1):331-9
pubmed: 21755340
Int J Gynecol Cancer. 2016 Sep;26(7):1190-5
pubmed: 27465891
Cancer Res. 2015 Sep 15;75(18):3832-41
pubmed: 26199092
Int J Mol Sci. 2016 Oct 20;17(10):
pubmed: 27775603
Genetics. 2013 Mar;193(3):651-69
pubmed: 23463798
Genes Dev. 2015 Mar 1;29(5):501-12
pubmed: 25737280
J Cancer. 2018 Jun 23;9(15):2693-2701
pubmed: 30087710
Cancer Lett. 2017 Dec 1;410:63-67
pubmed: 28947138
Oncogene. 2009 Nov 5;28(44):3926-36
pubmed: 19684618
Hum Pathol. 2014 May;45(5):942-51
pubmed: 24746199
Int J Mol Med. 2017 Apr;39(4):900-906
pubmed: 28259961
PLoS One. 2015 Jan 24;10(1):e0114851
pubmed: 25617627
BMC Cancer. 2015 Aug 15;15:590
pubmed: 26275425
Int J Oncol. 2015 May;46(5):2125-37
pubmed: 25695231
Oncotarget. 2015 May 10;6(13):11652-63
pubmed: 25871474
Nat Rev Genet. 2008 Nov;9(11):831-42
pubmed: 18852696
Nat Rev Cancer. 2016 Jan;16(1):35-42
pubmed: 26667849
Int J Clin Exp Pathol. 2013 Sep 15;6(11):2460-7
pubmed: 24228108
Oncogenesis. 2017 Jan 23;6(1):e288
pubmed: 28112720
Nucleic Acid Ther. 2013 Feb;23(1):29-34
pubmed: 23205572
Oncotarget. 2017 Jul 11;8(28):46090-46103
pubmed: 28545023
Oncol Lett. 2012 Dec;4(6):1290-1296
pubmed: 23226804
J Mol Histol. 2013 Oct;44(5):545-54
pubmed: 23529758
Cell Physiol Biochem. 2018;48(1):274-284
pubmed: 30007968
Cell Physiol Biochem. 2016;40(1-2):287-296
pubmed: 27855366
Int J Gynecol Cancer. 2016 Oct;26(8):1390-8
pubmed: 27648712
Am J Transl Res. 2017 Dec 15;9(12):5496-5506
pubmed: 29312501
Int J Cancer. 2014 Dec 15;135(12):2770-82
pubmed: 24771207
Curr Opin Cell Biol. 2009 Jun;21(3):470-9
pubmed: 19411171
PLoS One. 2014 Nov 25;9(11):e110674
pubmed: 25422887
Biochem Biophys Res Commun. 2016 Sep 16;478(2):507-12
pubmed: 27381864
Genome Res. 2018 Feb 2;:
pubmed: 29429977
Eur Rev Med Pharmacol Sci. 2016 Apr;20(8):1521-5
pubmed: 27160124
Tumour Biol. 2016 Jul;37(7):9451-63
pubmed: 26781979
Cancer Chemother Pharmacol. 2014 Mar;73(3):569-76
pubmed: 24448637
Mol Cell Biochem. 2012 Jan;360(1-2):301-7
pubmed: 22009483
Oncotarget. 2017 May 16;8(20):33137-33143
pubmed: 28388535
Lancet Oncol. 2015 Jan;16(1):98-107
pubmed: 25498219
Genes Dev. 2015 Mar 1;29(5):538-54
pubmed: 25737282
Oncogene. 2014 Apr 17;33(16):2110-22
pubmed: 23665676
Oncotarget. 2015 Nov 3;6(34):36535-50
pubmed: 26431492
Anticancer Res. 2016 Dec;36(12):6521-6526
pubmed: 27919977
J Exp Clin Cancer Res. 2016 Feb 03;35:25
pubmed: 26842910
Gynecol Oncol. 2012 Jan;124(1):125-33
pubmed: 22015043
J Pathol. 2015 Jul;236(3):348-59
pubmed: 25757065
Oncotarget. 2015 Nov 3;6(34):36675-88
pubmed: 26452132
Int J Gynecol Cancer. 2014 May;24(4):635-42
pubmed: 24758900
Oncotarget. 2015 Oct 20;6(32):33587-601
pubmed: 26384350
World J Gastroenterol. 2014 Nov 14;20(42):15736-44
pubmed: 25400457
Cancer Biol Ther. 2015;16(9):1308-15
pubmed: 26176806
Pathol Oncol Res. 2017 Oct;23(4):899-905
pubmed: 28795345
Oncotarget. 2015 Dec 1;6(38):40507-18
pubmed: 26439689
Oncotarget. 2015 Nov 24;6(37):39740-55
pubmed: 26452028
Cancer Lett. 2013 Sep 1;337(2):293-300
pubmed: 23587796
Hum Reprod. 2012 Oct;27(10):3036-45
pubmed: 22904162
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Pancreas. 2017 Mar;46(3):323-334
pubmed: 28099248
Int J Cancer. 2014 Oct 15;135(8):1790-9
pubmed: 24585547
Cancer Lett. 2014 Apr 1;345(1):39-47
pubmed: 24333727